Immunogenic cd1d binding peptides
AssigneeImcyse SA
InventorLuc VANDER ELST
Life of this patent
Estimating the term…
Abstract
The invention relates to isolated immunogenic peptides comprising a CD1d binding peptide, and immediately adjacent or separated from said CD1d binding peptide, a redox motif sequence which is further flanked by a histidine or tryptophan amino acids. The invention further relates to these peptides for use as a medicament The invention further relates to methods wherein these peptides are used for generating NKT cells which are cytolytic against cells presenting the cognate antigen.
Claims14
1-15. (canceled)
A method of treating an allergic disorder or autoimmune disease in a subject, comprising the step of administering to said subject an effective amount of a fusion peptide of between 12 and 100 amino acids wherein said fusion peptide comprises:
- (i) a first peptide of an antigen comprising the [FWYH]-X(2)-[VILM]-X(2)-[FWYH] (SEQ ID NO:
- 61) first sequence motif, wherein the antigen is myelin oligodendrocyte glycoprotein (MOG), and
- (ii) a [HW]-X(0,2)-C-X(2)-C ((SEQ ID NO:
- 7), (SEQ ID NO:
- 8), (SEQ ID NO:
- 9)) or C-X(2)-C-X(0,2)-[HW] ((SEQ ID NO:
- 10), (SEQ ID NO:
- 11), (SEQ ID NO:
- 12)) redox motif sequence, which is immediately adjacent or separated by at most 7 amino acids from said first sequence motif.
The method according to claim 1, wherein said fusion peptide comprises the sequence of HCGPCGGFLRVPCWKI (SEQ ID NO:
- 87), WCGPCGGFLRVPCWKI (SEQ ID NO:
- 88), HCHGCGGFLRVPCWKI (SEQ ID NO:
- 105), or WCHGCGGFLRVPCWKI (SEQ ID NO:
- 106).
A method of treating an allergic disorder or autoimmune disease in a subject, comprising the step of administering to said subject an effective amount of a population NKT cells which are cytolytic against cells presenting an antigen obtained by
- in vitro contacting peripheral blood cells with a fusion peptide of between 12 and 100 amino acids wherein said fusion peptide comprises:
- (i) a first peptide of the antigen comprising the [FWYH]-X(2)-[VILM]-X(2)-[FWYH] (SEQ ID NO:
- 61) first sequence motif, wherein the antigen is myelin oligodendrocyte glycoprotein (MOG), and
- (ii) a [HW]-X(0,2)-C-X(2)-C ((SEQ ID NO:
- 7), (SEQ ID NO:
- 8), (SEQ ID NO:
- 9)) or C-X(2)-C-X(0,2)-[HW] ((SEQ ID NO:
- 10), (SEQ ID NO:
- 11), (SEQ ID NO:
- 12)) redox motif sequence, which is immediately adjacent or separated by at most 7 amino acids from said first sequence motif
- expanding said cells in the presence of interleukin 2.
Dependencies are inferred from the claim text.